Why Your Pharmacy Won't Compound CJC-1295 (But Another Will)
One clinic says yes. Another says "we can't touch that." Both are following the law. The problem is that the law on peptide compounding is a patchwork — three pathways, three categories, overlapping bulks lists, and active litigation that has paused FDA enforc
One clinic says yes. Another says "we can't touch that." Both are following the law. The problem is that the law on peptide compounding is a patchwork — three pathways, three categories, overlapping bulks lists, and active litigation that has paused FDA enforcement. Here's the map.
The Three Legal Pathways for Compounding
Every compounded medication in the United States is made under one of three frameworks:
503A — Traditional pharmacy. A state-licensed pharmacy compounds a medication for a specific patient in response to a specific prescription. Regulated primarily by state pharmacy boards. Not required to meet cGMP (current Good Manufacturing Practice) standards. FDA steps in only for serious violations. This is where most peptide compounding happens.
503B — Outsourcing facility. Voluntarily registers with the FDA, subject to direct FDA inspection, must meet full cGMP standards, and can produce bulk stock without a patient-specific prescription. These are closer to pharmaceutical manufacturers. The oversight cost is high, so 503B facilities are strict about what they'll compound.
FDA-approved drug. Regular pharmaceutical manufacturing. Not compounding. Most peptides have never reached this pathway — it requires clinical trials, an NDA, and FDA approval.
A pharmacy can only legally compound a substance if it meets at least one of three criteria: the substance has a USP or NF monograph, the substance is a component of an FDA-approved drug, or the substance appears on the FDA's 503A Bulk Drug Substances List. If a peptide hits none of those three boxes, compounding it is technically outside the law — regardless of how common the practice is.
The Category System (Created September 2023)
In September 2023 the FDA formalized how it treats bulk drug substances that are nominated for the 503A list but haven't yet been evaluated. It created three categories:
Category 1
Under evaluation, no significant safety concerns
Enforcement discretion — green light
Pharmacies can compound with low regulatory risk
Category 2
Potential safety concerns identified
No enforcement discretion — red light
Pharmacies compounding these face FDA action
Category 3
Procedurally disqualified
Not eligible
Nominations did not meet basic criteria
On September 29, 2023, the FDA dropped 19 popular peptides into Category 2 in one coordinated move. That's the event that created the modern "peptide ban" narrative. It included BPC-157, TB-500, CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604, GHK-Cu, selank, semax, epitalon, and others. Overnight, every conservative compounding pharmacy stopped filling prescriptions for these peptides.
Why Pharmacies Disagree — It's Risk Tolerance
The law is the same for everyone. What differs is how much risk each pharmacy will absorb.
Conservative 503A pharmacies. Read "Category 2" as "do not compound." Won't touch anything not explicitly on the 503A Bulks List. State pharmacy boards and malpractice carriers both treat Category 2 compounding as a red flag that can trigger investigation or coverage denial. These pharmacies say no to CJC-1295, ipamorelin, BPC-157, TB-500, and anything else in regulatory limbo.
Permissive 503A pharmacies. Read "under review" as "not yet prohibited." They lean on the active litigation (Fagron Compounding Services and others sued the FDA over the peptide categorization process, which has effectively suspended enforcement) to continue compounding. They accept the legal exposure because patient demand and margin make it worth it. These pharmacies will compound CJC-1295, ipamorelin, and many of the other 19 listed peptides right now.
503B outsourcing facilities. The strictest of the three. They face direct FDA inspection and can lose their registration over a single violation. No 503B facility is compounding Category 2 peptides — the risk of losing federal authorization is too high. If you see a peptide advertised as "503B compounded," it's either sermorelin, tesamorelin, or a peptide already on the 503B Bulks List.
This is why you can call three clinics and get three different answers about the same peptide. All three can be correct within their own risk tolerance.
Why Sermorelin Is Everywhere But CJC-1295 Isn't
Both are growth hormone releasing hormone analogs. Both stimulate GH release. One is in every longevity clinic in America. The other is a regulatory landmine. Why?
Sermorelin was FDA-approved under NDA 020443 for pediatric growth hormone deficiency. The branded product was voluntarily discontinued by its manufacturer in 2008 for business reasons, not safety. But the FDA approval still counts — sermorelin is a "component of an FDA-approved drug," which is one of the three qualifying criteria for 503A compounding. That's why sermorelin has never been on the Category 2 list and why virtually every compounding pharmacy will make it.
CJC-1295 has never been FDA-approved for anything. It has no USP monograph. It was nominated for the 503A Bulks List, placed into Category 2 in September 2023, then removed from Category 2 in September 2024 (the nominators voluntarily withdrew). In October and December 2024 the Pharmacy Compounding Advisory Committee reviewed ipamorelin and CJC-1295 and voted against 503A Bulks List inclusion. So CJC-1295 is now in regulatory no-man's-land: not Category 2 anymore, but also not approved for compounding via any of the three pathways.
Semaglutide is a third case study. It's FDA-approved as a branded product, which normally disqualifies it from compounding. But while it was on the FDA drug shortage list in 2023-2024, compounding pharmacies could legally prepare it under Section 506 of the FD&C Act. When the FDA declared the shortage resolved, that pathway closed. This is why hundreds of telehealth clinics stopped offering compounded semaglutide in 2025.
The April 15, 2026 Kennedy Announcement
This is where it gets interesting. On April 15, 2026, HHS Secretary Robert F. Kennedy Jr. directed the FDA to remove 12 peptides from Category 2. The removal is effective April 22, 2026.
The 12 peptides:
BPC-157
TB-500 (Thymosin Beta-4 Fragment)
KPV
MOTS-c
Epitalon
Semax
DSIP
LL-37
Dihexa
GHK-Cu
PEG-MGF
Melanotan II
Critical nuance: removal from Category 2 is not the same as approval for compounding. Those peptides still fail the three qualifying criteria (no USP monograph, not FDA-approved, not on the 503A Bulks List). The path forward is the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, where the committee will vote on whether to add BPC-157, KPV, TB-500, and MOTS-c to the 503A Bulks List. The remaining peptides in the list of 12 will be reviewed in subsequent PCAC meetings through February 2027.
If you want the committee to hear from you before the July vote, the public comment deadline is July 9, 2026. Comments received after that date go to FDA staff but not the voting committee.
CJC-1295 and Ipamorelin: Still in Limbo
The two most popular growth hormone peptides have a stranger regulatory status than almost anyone realizes.
Timeline:
September 2023: Placed into Category 2. All compounding effectively stops.
September 20, 2024: FDA announces five bulk drug substances including CJC-1295 and ipamorelin acetate are being removed from Category 2 because nominators withdrew their nominations. Effective September 27, 2024.
October 29, 2024: PCAC reviews ipamorelin (acetate and free base), ibutamoren mesylate, L-theanine, and kisspeptin-10. FDA's own analysis recommends none of these be included in the 503A Bulks Regulation. PCAC mostly votes against inclusion.
December 4, 2024: PCAC reviews CJC-1295 variants. Votes against 503A Bulks List inclusion.
Present: Neither peptide is on the 503A Bulks List. Neither is in Category 2. They sit in regulatory no-man's-land.
Meanwhile, the active litigation over the FDA's peptide categorization process has suspended enforcement. That means a 503A pharmacy compounding ipamorelin today is not technically in compliance with the 503A criteria, but also is not being enforced against. Some pharmacies treat this as a safe window. Others treat it as a loaded gun they'd rather not hold.
This is why you get inconsistent answers. One pharmacist says "we don't compound ipamorelin, it's not on the Bulks List." Another pharmacist at the next clinic over says "we compound it all the time, nothing has changed." Both are accurately describing the same regulatory reality from opposite sides of the risk threshold.
What This Means for You
Your access depends on which category your peptide falls into.
Peptides with a clear green light (on the 503A Bulks List or components of approved drugs): sermorelin, tesamorelin, NAD+, oxytocin. Any willing compounding pharmacy can fill a prescription. Price and quality vary; legality does not.
Peptides just removed from Category 2, awaiting PCAC vote (BPC-157, TB-500, KPV, MOTS-c, plus eight others): Still cannot be legally compounded until the PCAC votes them onto the 503A Bulks List and the FDA issues a final rule. July 23-24 is the first vote. Don't expect compounding pharmacy access before late 2026 at the earliest.
Peptides in regulatory no-man's-land (CJC-1295, ipamorelin): Not in Category 2, not on the Bulks List, PCAC already voted against inclusion. Whether your prescription gets filled depends entirely on your pharmacy's risk tolerance. Some will, most won't. 503B outsourcing facilities won't touch them.
Peptides still in Category 2 (seven of the original 19 not removed on April 15): GHRP-2, GHRP-6, CJC-1295 (note: variants of CJC-1295 are in multiple buckets), kisspeptin-10, and others remain flagged for potential safety concerns. Compounding is an enforcement risk for any pharmacy.
Research-use-only vendors: Not affected by any of this. They operate under a separate regulatory framework (research chemicals sold for laboratory use, not human consumption). Inventory of BPC-157, TB-500, CJC-1295, ipamorelin, and the full spectrum of peptides remains available. This is the path most consumers still use.
If you've been trying to figure out why one clinic prescribes CJC-1295 and another refuses — now you know. They're both following the law. They're just making different bets on how the FDA will enforce it.
Want a compounded peptide today? For anything not on the 503A Bulks List, availability depends on your pharmacy's risk appetite. For research-grade supply, see the vetted vendors below — inventory, COAs, and current pricing.